Immunic Q3 Loss Widens to $42.3M; $132M Cash Funds Operations Past 12 Months
IMUX sits 52% above its 52-week low of $5.062.
Summary
Immunic posted a $42.3 million Q3 2026 net loss, up from $25.6 million a year ago, driven largely by non-cash stock compensation from its CEO transition. The quarter ended with $132.0 million in cash, enough to fund operations beyond twelve months, and ENSURE Phase 3 topline data is expected in December 2026.
Key Events · Earnings and Guidance · IMUX
-
Q3 Net Loss Widens to $42.3M
For the three months ended September 30, 2026, net loss was $42.3 million versus $25.6 million a year earlier; the nine-month loss reached $109.0 million.
-
G&A Jump Driven by Non-Cash Comp
General and administrative expense rose 225% to $19.4 million, including $9.7 million of non-cash stock compensation primarily tied to the former CEO's separation agreement.
-
R&D Up 20% on NDA Readiness
Research and development expense rose to $23.9 million from $20.0 million, reflecting NDA readiness activities and vidofludimus calcium drug supply.
-
Cash Runway Beyond Twelve Months
Cash and cash equivalents stood at $132.0 million at September 30, 2026, which management expects to fund operations beyond twelve months.
Analysis · IMUX · Life Sciences
The headline loss widened sharply, but the driver is largely non-cash: general and administrative expense jumped 225% to $19.4 million, of which $9.7 million was stock compensation tied to the former CEO's separation agreement. Research and development rose 20% to $23.9 million as the company spends on NDA readiness and drug supply ahead of the pivotal ENSURE Phase 3 readout, now guided to December 2026. With $132.0 million in cash, management says operations are funded beyond twelve months, so the near-term story is the ENSURE data rather than liquidity.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMUX was trading at $7.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $106.3M. The 52-week trading range was $5.06 to $17.43. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.